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ABSTRACT 
Environmental or lifestyle factors are likely to explain part of the heterogeneity in breast 
and ovarian cancer risk among BRCA1 and BRCA2 mutation carriers. We assessed parity 
as a risk modifier in 515 and 503 Spanish female carriers of mutations in BRCA1 and 
BRCA2, respectively. Hazard ratios (HR) and their corresponding 95% confidence 
intervals (CI) were estimated using weighted Cox proportional hazards regression, 
adjusted for year of birth and study centre. The results for ever being parous and number 
of live-births were very similar for carriers of mutations in both genes. For all mutation 
carriers combined, the estimated HR associated with ever having had a live-birth was 
0.74 (95% confidence interval [CI]=0.55-1.01, p=0.06), and that associated with each 
live-birth was 0.87 (95%CI=0.77-0.98, p=0.02). The latter association was observed only 
in women aged 40 and above (HR=0.81, 95%CI=0.70-0.94, p=0.004 versus HR=0.99, 
95%CI=0.83-1.18, p=0.9 for women under age 40), and this trend was highly consistently 
observed for carriers of mutations in each gene. There was no evidence of an association 
between breast cancer risk and age at first birth for parous BRCA1 or BRCA2 mutation 
carriers (p-trend>0.3). The power to detect associations with ovarian cancer risk was 
much lower, especially for BRCA2 mutation carriers. Nevertheless, having a live-birth 
was associated with protection for BRCA1 mutation carriers (HR=0.41, 95%CI=0.18-
0.94, p=0.03), and a strong and consistent protective effect of age at first birth was 
observed for parous carriers of mutations in both genes (HR=0.65, 95%CI=0.52-0.83, 
p<0.001). This is the third independent study to find that, as in the general population, 
parity appears to be associated with protection from breast cancer in women with 
mutations in BRCA1 and BRCA2. Parity appears to be protective for ovarian cancer in 
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BRCA1 mutation carriers, but its role in BRCA2 mutation carriers remains unclear. 
Whether later age at first birth is also protective for ovarian cancer in mutation carriers 
requires further confirmation.  
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INTRODUCTION 
The incomplete penetrance of mutations in the breast and ovarian cancer susceptibility 
genes BRCA1 and BRCA2 suggests that there are other genetic and/or environmental 
factors that modify the risk of these cancers in female mutation carriers. Additional 
evidence of risk modifiers includes the general observation that estimates of penetrance 
tend to be higher in studies of multiple-case families than in studies of families of cases 
unselected for family history [1], as well as the more recent finding that the proportion of 
breast cancer fenocopies (cases of cancer in non-carrier members of a mutation-carrying 
family) is greater than that expected according to the disease incidence in the general 
population [2-4]. Both results suggest that other genetic and/or non-genetic factors may 
accumulate in some families and influence the risk of cancer in carriers and non-carriers 
alike. More specific evidence of the existence of non-genetic modifiers, of breast cancer 
risk in particular, comes from the consistent observation that the penetrance of BRCA1 
and BRCA2 mutations has increased over the last century [1, 5-8]. Environmental or 
lifestyle factors, rather than genetic factors, are most likely to explain this trend.  
 
The identification of these risk-modifying factors for mutation carriers is important for 
several reasons. Firstly, providing these women with information about what they can do 
with respect to environmental and lifestyle factors to reduce their risk of cancer may be 
an important complement to screening programs, and a possible alternative to invasive  
prophylactic surgical interventions. Secondly, the incorporation of these factors into 
penetrance estimation will lead to more accurate risk modelling and therefore better 
informed genetic counselling. 
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It is not clear whether established risk factors for breast and/or ovarian cancer in the 
general population, such as parity [9, 10], act as risk modifiers in carriers of mutations in 
BRCA1 and BRCA2. Various studies have investigated such factors as modifiers, but all 
are subject to potential biases due to the way in which mutation carriers are recruited, and 
few definitive conclusions have been reached [11]. While prospective studies of cohorts 
of unaffected carriers are considered best placed to clarify this issue, these will take time 
to accumulate a sufficient number of incident cancer cases for analysis. It is therefore 
important that, at least until results from prospective studies become available, the largely 
retrospective data at hand are taken advantage of to make appropriate inference. Results 
that are consistently observed across multiple studies are likely to be most reliable. 
 
It has been established in the general population that an increasing number of children is 
associated with protection from both breast and ovarian cancer [9, 12, 13]. Later age at 
first birth is associated with increase risk of breast cancer [9], but possibly a reduced risk 
of ovarian cancer [13]. Parity has been evaluated as a breast cancer risk modifier in a 
number of studies of mutation carriers [14-20], with largely contradictory results. There 
are fewer published studies of modifiers of ovarian cancer risk [15, 21, 22]. We aimed to 
assess parity (ever parous, number of full-term pregnancies and age at first full-term 
pregnancy) as a modifier of breast cancer risk and ovarian cancer risk in carriers of 
mutations in BRCA1 and BRCA2 recruited by 13 genetic counselling centres in Spain.  
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METHODS 
Subjects 
All female carriers of deleterious mutations in BRCA1 and BRCA2 recruited at 13 genetic 
counselling centres in Spain (see Table 1) were considered eligible. These included: (i) 
799 mutation carriers recruited by 12 centres between 1995 and 2006 from the 319 
families included in our previous penetrance study [5]; (ii) 235 mutation carriers from 
235 families in which, as at 31
st
 December, 2006, they were the only individual that had 
tested positive (which meant that they were excluded from the penentrance study, [5]); 
(iii) 89 mutation carriers from 42 families recruited by the Hospital Vall d´Hebrón in 
Barcelona between 2005 and 2008; and (iv) 107 obligate carriers (untested women with 
at least one decendent and one other non-decendent blood relative who had tested 
positive for the same mutation) from families recruited at all 13 centres. 
 
Family selection, mutation testing and other data collection methods have been described 
previously [5]. Briefly, the youngest member affected with breast and/or ovarian cancer 
from families with multiple cases of these cancers was generally the first tested for 
mutations in BRCA1 and/or BRCA2. When a mutation was detected, that specific mutation 
was tested for in additional family members. Mutations were defined as deleterious if they 
were classified as clinically important by the Breast Information Core (BIC, 
http://research.nhgri.nih.gov/bic/) or they met other widely accepted criteria [5]. 
Information on year of birth, breast and ovarian cancer status, age at diagnosis of breast 
and/or ovarian cancer (if applicable), current age, age at death (if deceased), age at 
prophylactic bilateral mastectomy (if applicable), and age at prophylactic oophorectomy (if 
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 8 
applicable), was collected on each family member as part of genetic counselling. We 
excluded eligible mutation carriers with missing data for any of these items, or for which 
the year of birth of at least one of their children was unknown.  
 
Statistical methods 
We compared the distribution of subjects across centres (CNIO, Sant Pau, HCSC, ICO, 
Vall d´Hebron, FPGMX, all others combined - for BRCA1 mutation carriers; and CNIO, 
Sant Pau, HCSC, ICO, Valencia, all others combined - for BRCA2 mutation carriers) 
between affected and unaffected mutation carriers using Pearson´s chi-squared test. The 
distributions of age at censoring (see below) and year of birth were compared by 
affection status using logistic regression, fitting each of these as continuous variables. 
 
Associations with the risk of breast and ovarian cancer were assessed separately for each 
of the parity variables considered, by estimating hazard ratios (HR) and their 
corresponding 95% confidence intervals (CI) using weighted multivariable Cox 
proportional hazards regression with robust estimates of variance [23]. For each mutation 
carrier, we modeled the time to diagnosis of breast or ovarian cancer from birth, 
censoring at the first of the following events: bilateral prophylactic mastectomy, bilateral 
prophylactic oophorectomy, breast cancer diagnosis, ovarian cancer diagnosis, death and 
date last know to be alive. For the analysis of breast cancer, subjects were considered 
affected if their age at censoring corresponded to their age at diagnosis of breast cancer 
and unaffected otherwise. For the analysis of ovarian cancer, subjects were considered 
affected if their age at censoring corresponded to their age at diagnosis of ovarian cancer 
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 9 
and unaffected otherwise. Weights were assigned separately for the breast and ovarian 
cancer analyses, by affection status, age and gene mutated, so that the weighted observed 
incidence rate agreed with established estimates [1], summarized as “external rates” in 
Antoniou et al. [23]. The age categories considered were <25, 25-29, 30-34, 35-39, 40-
44, 45-49, 50-54, 55-59, 60-64, 65-69 and >70, with the first three categories combined 
for the ovarian cancer analysis due to the small number of affecteds observed. These 
weights have been shown to correct for the bias inherent in the oversampling of affected 
women due to the ascertainment criteria applied [23].  
 
We evaluated associations with parity (nuliparous, parous), number of live births (0, 1, 2, 
3, >4) and age at first live birth (15-19, 20-24, 25-29, >30), with trends assessed for the 
latter two based on the corresponding continuous variables. For the analysis of categories 
of age at first live birth, 20-24 was used as the reference group because it was the most 
common. All these measures were modeled as time-varying variables. Additional 
independent variables included in all analyses were year of birth (<1930, 1930-1939, 
1940-1949, 1950-1959, 1960-1969, >1970) and centre (in defined above and presented in 
Table 2).  Heterogeneity in HRs by age was assessed based on the Wald-statistic p-value 
corresponding to the interaction term for the variable in question, by age (dichotomized 
into (<40, >40). Mutation carriers from the present study included in previous studies of 
parity as a modifier of cancer risk by the International BRCA1/2 Carrier Cohort Study 
(IBCCS) [17, 22] were excluded and weights recalculated in sensitivity analysis. The 
influence of survival bias was evaluated by repeating all analyses (based on re-calculated 
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weights) after excluding affecteds who were genetically tested more than three years after 
their breast cancer diagnosis, or more than one year after their ovarian cancer diagnosis.  
 
All statistical analyses were carried out using Stata: Release 10 [24]. Robust estimates of 
variance were calculated using the cluster subcommand, applied to an identifier variable 
unique to each family. All p-values were two-sided and those less than 0.05 were 
considered statistically significant. 
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RESULTS 
Of the 626 eligible BRCA1 mutation carriers and 604 eligible BRCA2 mutation carriers, 
515 (82%) and 503 (83%), respectively, were included in the analyses of parity as a risk 
modifier. Details are given in Table 1. These were members of 253 and 246 famlies, 
respectively. The distrubition of the number of carriers per family were very similar for 
BRCA1 and BRCA2 mutations, with, overall, 51% of families with just one member, 23% 
with two, 13% with three, 6% with four, 3% with five, 2% with six, 1% with seven and 
less than 1% of families with eight or more members represented in the dataset. Table 2 
summarises the characteristics of included mutation carriers according to affection status, 
and gene mutated. For ovarian cancer, but not breast cancer, affecteds tended to be older 
than unaffecteds, regardless of the gene mutated (both p < 0.001). For carriers of 
mutations in both genes and for both cancers, affected women tended to be born before 
unaffected women (all p ≤ 0.001). 
 
Associations with breast cancer risk 
Results from the multivariable analysis of the three parity variables and breast cancer risk 
are summarized in Table 3. The results for ever being parous and number of live-births 
were very similar for carriers of mutations in BRCA1 and BRCA2, with HR estimates 
below 1, although none were statistically significant (all p > 0.08). After combining 
mutation carriers in both genes, the estimated HR associated with ever having had a live-
birth was 0.74 (95% confidence interval [CI]=0.55-1.01, p=0.06), and that associated 
with each live-birth was 0.87 (95%CI=0.77-0.98, p=0.02). Analyses stratified by age 
suggested that this association with number of live-births was only apparent in women 
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aged 40 and above (HR=0.81, 95%CI=0.70-0.94, p=0.004 versus HR=0.99, 
95%CI=0.83-1.18, p=0.9 for women under age 40). While the difference in HR by age 
was not statistically significant (p=0.1), this result was consistently observed for BRCA1 
mutation carriers (HR=0.82, 95%CI=0.69-0.98, p=0.03 for women aged 40 and above 
and HR=1.02, 95%CI=0.81-1.29, p=0.9 for younger women) and BRCA2 mutation 
carriers (HR=0.81, 95%CI=0.63-1.04, p=0.09 and HR=0.97, 95%CI=0.74-1.28, p=0.8, 
respectively). We observed no evidence of an association between breast cancer risk and 
age at first birth for parous BRCA1 or BRCA2 mutation carriers (both p-trend ≥ 0.3).  
 
There were 67 mutation carriers that were included in a previous study of parity and 
breast cancer risk by the IBCCS [17], 38 with mutations in BRCA1 and 29 with mutations 
in BRCA2. Excluding these made no substantial difference to the results obtained. The 
estimated HR per live-birth was 0.86 for BRCA1 mutation carriers, 0.90 for BRCA2 
mutation carriers and 0.87 (p=0.03) for all carriers combined. The corresponding HR 
estimates for women aged less than 40 were 0.96, 1.03 and 0.97, respectively, while those 
for women aged 40 and above were 0.82, 0.83 and 0.81 (p=0.008), respectively.  There 
were 299 affected mutation carriers who were diagnosed with breast cancer more than 
three years prior to their mutation testing, 154 with mutations in BRCA1 and 145 with 
mutations in BRCA2. Excluding these similarly made no substantial difference to the 
results obtained. The estimated HR per live-birth was 0.77 for BRCA1 mutation carriers, 
0.88 for BRCA2 mutation carriers and 0.79 (p=0.002) for all mutation carriers combined. 
 
Associations with ovarian cancer risk 
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Results from the multivariable analyses of the three parity variables and ovarian cancer 
risk are also summarized in Table 3. For BRCA1 mutation carriers, ever having had a 
live-birth was associated with reduced risk of ovarian cancer (HR=0.41, 95%CI=0.18-
0.94, p=0.03). There was some evidence of a dose-response effect, with BRCA1 mutation 
carriers with four or more children at even lower estimated risk relative than those with 
no children (HR=0.15, 95%CI=0.04-0.56, p=0.005), but the trend per birth was not 
statistically significant (HR=0.80, 95%CI=0.61-1.05, p=0.1). There was no evidence of 
association with number of live-births for BRCA2 mutation carriers (all p ≥ 0.3). Age at 
first birth appeared to be inversely associated with ovarian cancer risk, with very similar 
HR estimates for BRCA1 and BRCA2 mutation carriers (p-trend=0.001 and 0.1 for 
BRCA1 and BRCA2 mutation carriers, respectively). The estimated HRs for carries of 
mutations in both genes combined, per five years of age, was 0.65 (95%CI=0.52-0.83, 
p<0.001). 
 
There were 116 mutation carriers that were included in a previous study of parity and 
ovarian cancer risk by the IBCCS [22], 59 with mutations in BRCA1 and 57 with 
mutations in BRCA2. Excluding these gave slightly stronger evidence of the associations 
reported above. For BRCA1 mutation carriers the estimated HRs were 0.32 (p=0.01) for 
ever having had a live-birth and 0.74 (p=0.04) per live-birth. The estimated HR 
associated with increments of 5 years in age at first birth was 0.64 (p=0.004) for BRCA1 
mutation carriers, 0.46 (p=0.02) for BRCA2 mutation carriers and 0.60 (p=0.001) for all 
carriers combined. There were 55 affected mutation carriers who were diagnosed with 
ovarian cancer more than one year prior to their mutation testing, 36 with mutations in 
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BRCA1 and 19 with mutations in BRCA2. Results were consistent after excluding these 
women. For BRCA1 mutation carriers the estimated HRs were 0.29 (p=0.007) for ever 
having had a live-birth and 0.72 (p=0.08) per live-birth. The estimated HR associated 
with increments of 5 years in age at first birth was 0.58 (p=0.03) for BRCA1 mutation 
carriers, 0.78 (p=0.5) for BRCA2 mutation carriers and 0.65 (p=0.04) for all carriers 
combined. It should be noted that there was likely to be over-fitting of these latter models 
due to the small number of affecteds in this reduced sample set (37 and 16 for BRCA1 
and BRCA2 mutation carriers, respectively).  
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DISCUSSION 
Parity and breast cancer risk 
We have evaluated the effect of parity on the risk of breast cancer in 515 BRCA1 
mutation carriers and 503 BRCA2 mutation carriers in Spain. After adjusting for study 
centre and year of birth, we observed evidence parity is associated with protection from 
breast cancer in BRCA1 and BRCA2 mutation carriers. Each live-birth was associated 
with an estimated 13% risk reduction. We observed no evidence of an association with 
age at first birth.  
 
The results from previous studies of the possible effect of parity on breast cancer risk in 
BRCA1 and BRCA2 mutation carriers have been mixed. They are summarized in Table 4. 
Jernstrom et al., [16] pooled data from carriers of mutations in both genes (although 80% 
had mutations in BRCA1) and found that parous carriers were at an estimate 71%  
increased risk of breast cancer compared to nuliparous carriers. They also observed a 
trend effect, with an estimated 24% increased risk per full-term pregnancy. This result 
was not replicated in a subsequent study by the same group, based on a much larger set of  
mutation carriers from 55 international collaborating centres [14], most (73%) in North 
America. They observed that for women with a BRCA1 mutation, having 4 or more 
children was associated with reduced breast cancer risk compared to being nulliparous. In 
contrast, among BRCA2 carriers, increasing parity was associated with an increased risk 
of breast cancer (15% per live-birth). A third study by some of the same authors [15], 
reported that for Polish BRCA1 mutation carriers, each live-birth was associated with an 
estimated 20% increased risk of breast cancer. All three studies matched unaffected 
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carriers to affected carriers on year of birth, country and gene mutated and estimated odds 
ratios (OR) using condition logistic regression. 
 
The IBCCS, a predominantly European consortium, has more recently published their 
analysis of parity as a potential modifier of breast cancer risk in mutation carriers [17]. 
They obtained similar results for carriers of mutations in BRCA1 and BRCA2. In a pooled 
analysis, they observed no effect associated with being parous, but among parous women, 
estimated that each live-birth was associated with a statistically significant 14% decrease 
in risk. This effect was only observed in women over age 40 years. This group also 
evaluated the effect of age at first live-birth and found marginally statistically significant 
evidence that it differed between BRCA1 and BRCA2 mutation carriers [17]. While for 
BRCA1 mutation carriers, having a child later in life appeared to be associated with 
protection, the opposite seemed to be the case for BRCA2 mutation carriers. Antoniou et 
al. [18] subsequently carried out a very similar analysis of a smaller set of mutation 
carriers from the United Kingdom and found that ever being parous was associated with 
an estimated 56% reduced risk for all mutation carriers combined, but again, only for 
women over age 40. For women of all ages, there was marginal evidence of a trend of 
decreasing risk with increasing parity. They also observed evidence that in parous BRCA2 
mutation carriers, risk is higher for those who have their first child later. Both these 
studies estimated HR using weighted Cox regression, adjusting for year of birth and other 
covariates.  
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Two other studies have examined the effect of age at first birth on breast cancer risk in 
mutation carriers. Rebbeck et al. [20] studied mostly (83%) BRCA1 mutation carriers and 
observed that those who had their first birth earlier were at reduced risk of breast cancer. 
Most recently, members of the aforementioned intenational consortium applied their 
matched case-control design to the largest set of mutation carriers studied to date [19]. 
They found no evidence of an association for all carriers combined and reported that this 
result was consistent in stratified analyses by gene mutated. 
 
Our results are consistent with those of the two other European studies that applied the 
same analytic approach [17, 23]. This approach adopted allows all mutation carriers with 
complete data to be included, in contrast to the majority of the other studies in which up 
to 40% of carriers were excluded because no matched-pair was found [14, 19]. The 
consistent results from these three independent studies suggest that, as for women in the 
general population, parity is associated with protection from breast cancer for women at 
high risk of the disease due to mutations in BRCA1 and BRCA2. This finding may be 
particularly relavent to unaffected mutation carriers who are concerned about the impact 
pregnancy may have on their own breast cancer risk. 
 
While our results are also consistent with there being no association between age at first 
birth and breast cancer risk in mutation carriers, the power of our study in this regard was 
limited (as discussed further below), and the estimated HRs for trend are in the same 
(opposing) directions as those reported by the two European studies [17, 18]. It is 
therefore difficult to reach any definitive conclusions in this regard. 
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Parity and ovarian cancer risk 
Regarding ovarian cancer risk, after adjusting for study centre and year of birth, we 
observed marginal evidence that for BRCA1 mutation carriers, ever having had a live-
birth is associated with protection. We also observed that for parous BRCA1, and possibly 
BRCA2, mutation carriers, later age at first birth is associated with protection.  
 
Three studies have evaluated parity as a modifier of ovarian cancer risk in mutation 
carriers. A Polish study of 300 BRCA1 mutation carriers found no evidence of association 
with number of live-births [15]. The previously mentioned international consortium 
studied 3,223 mutation carriers, and observed that while women with BRCA1 mutations 
(84% of their sample) appeared to be protected from ovarian cancer both by ever having 
had full-term pregnancy (OR=0.67, 95%CI=0.46-0.96, p=0.03) and with increasing parity 
(OR=0.87 per birth, 95%CI=0.79-0.95, p=0.003), parous BRCA2 mutation carriers were 
at increased risk (OR=2.74, 95%CI=1.18-6.41, p=0.02) [21]. The authors did not assess 
age at first birth as a risk modifier. Finally, the IBCCS has recently reported on their 
study of larger sample of 2,281 BRCA1 and 1,038 BRCA2 mutation carriers [22]. It also 
observed evidence that among parous BRCA1 mutation carriers, ovarian cancer risk 
decreased with each live-birth after the first (p=0.002), but that risk was also reduced for 
those who were nulliparous, relative to those who had had just one live-birth (p=0.02). 
No definitive conclusions were reached regarding the effect of parity for BRCA2 
mutation carriers. No evidence of an association with ovarian cancer risk was seen for 
age at first birth.  
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Our finding that later age at first birth is associated with reduced risk of ovarian cancer in 
mutation carriers is consistent with what has been observed in the general population, 
based on two large [25, 26] (and a combined analysis of smaller [13]) population-based 
case-control studies, although inconsistent findings have been reported from much 
smaller, hospital-based studies [13, 27, 28]. Further investigation is warranted to clarify 
this issue. 
 
Study biases and limitations 
Our study, like those of the IBCCS and the UK group [17, 18, 22], sought to account for 
the potential biases inherent in these studies of a highly selected and related sample of 
mutation carriers by modeling time from birth to diagnosis of breast or ovarian cancer in 
carriers using weighted Cox regression. Weights were calculated to correct for the over-
representation of affected individuals at all ages, assuming that the age-specific incidence 
rates for breast and ovarian cancer in carriers of mutations in both genes estimated by 
Antoniou et al. (2003) are applicable [23]. Our recent study of the penetrance of 
mutations in BRCA1 and BRCA2 in Spanish multiple-case families indicated that this 
assumption is valid [5]. That our results were maintained after exluding prevalent cases 
suggests that survival bias was not present.  
 
While we attempted to include obligate carriers wherever possible, in general, a mutation 
carrier had to be genetically tested in order to be included in the analysis. A further 
potential bias in this study would therefore be present if affected and unaffected women 
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were influenced by parity in different ways in terms of their decision to undergo genetic 
testing. It may be, for example, that women who have already been diagnosed with breast 
or ovarian cancer are more influenced in this decision by whether or not they have 
children (at potential genetic risk of the disease), than are unaffected women and this may 
result in bias in HR estimation. However, it could be hypothesized that this would tend to 
bias HR estimates in the direction of increased risk associated with being parous, rather 
than towards the observed protection. 
 
One of the limitations of our study was that we measured time to cancer diagnosis and 
age at first birth in years, rather than months or days. This would have reduced the power 
to detect associations, but is unlikely to have introduced bias in HR estimation. Another 
potential limitation was that we were not able to adjust for potential confounding factors 
such as education level and other hormonal risk factors because we did not systematically 
collect this information on all mutation carriers. However, other studies were able to 
adjust for most of these factors and found that this had little impact on parity-associated 
HR estimates for breast and ovarian cancer [17, 21]. Finally, the number of mutation 
carriers with ovarian cancer was relatively low, particularly with regard to BRCA2, and so 
the corresponding results should be interpreted with greater caution. 
 
Conclusions 
This is the third independent study to find that, as in the general population, parity 
appears to be associated with protection from breast cancer in women with mutations in 
BRCA1 and BRCA2. Nevertheless, results have not been consistent across all studies and 
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their retrospective designs imply a number of potential biases. Prospective studies of 
mutation carrier cohorts are therefore likely to be highly informative in this regard.  
Parity also appears to confer protection from ovarian cancer, at least for BRCA1 mutation 
carriers. Whether this is the case for BRCA2 mutation carriers remains to be confirmed. It 
may be that later age at first birth is associated with protection from ovarian cancer in 
both BRCA1 and BRCA2 mutation carriers, as has been observed in the general 
population, but again, this finding requires confirmation in independent studies. 
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Table 1: Number of eligible and included carriers of mutations in BRCA1 and  BRCA2, by centre. 
 
 
Centre
a
 
 
 
Carriers from families included in the 
penetrance study [5] 
 
Sole mutation 
carriers
b
 
 
All mutation 
carriers 
 
Proportion of 
eligible mutation 
carriers included 
Tested Obligate 
Included/Eligible
c
 Included/Eligible
c
 Included/Eligible
c
 Included/Eligible
c
 
BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1    BRCA2 
CNIO 
Sant Pau 
HCSC 
ICO 
Vall d´Hebron
d
 
FPGMX 
Valencia 
Valladolid 
Castellón 
Barakaldo 
Zaragoza 
Elche 
Salamanca 
69/84 
63/64 
63/72 
41/43 
 
49/58 
6/6 
  4/17 
12/12 
5/5 
9/10 
7/7 
2/5 
4/121 
69/72 
52/57 
57/58 
 
6/8 
43/43 
1/8 
12/12 
18/18 
5/6 
7/7 
3/6 
1/7 
12/16 
  1/16 
7/9 
 
0/3 
0/0 
2/4 
3/3 
0/0 
0/0 
0/2 
0/0 
3/6 
7/8 
  0/11 
4/4 
 
0/0 
4/4 
0/2 
1/1 
1/2 
0/0 
2/2 
0/1 
35/37 
11/11 
14/15 
4/4 
 
10/12 
3/3 
16/27 
0/0 
0/0 
5/5 
1/1 
0/0 
20/26 
7/7 
20/20 
3/3 
 
0/1 
3/5 
31/50 
0/0 
0/0 
4/7 
1/1 
0/0 
105/128 
86/91 
  78/103 
52/56 
60/68 
59/73 
9/9 
22/48 
15/15 
5/5 
14/15 
  8/10 
2/5 
117/153 
83/87 
72/88 
64/65 
25/27 
6/9 
50/52 
32/60 
13/13 
19/20 
  9/13 
10/10 
3/7 
  82% 
  95% 
  76% 
  93% 
  88% 
81%        
100% 
  46% 
100% 
100% 
  93% 
  80% 
  40% 
  76% 
  95% 
  82% 
  98% 
 93%  
 67% 
  96% 
  53%   
100% 
  95% 
  69% 
100% 
  43% 
Total 330/383 367/416 26/60 22/41   99/115   89/120 515/626 503/604   82%   83% 
a The 12 participating centres were the Centro Nacional de Investigaciones Oncológicas, Madrid (CNIO); the Hospital de la Santa Creu i Sant Pau, Barcelona (Sant Pau); the 
Hospital Clínico San Carlos, Madrid (HCSC); the Institut Català d’Oncologia, Barcelona (ICO); the Hospital Vall d´Hebron, Barcelona (Vall d´Hebron); the Fundación Pública 
Galega de Medicina Xenómica, Santiago de Compostela (FPGMX); the Hospital Clínico Universitario de Valencia, Valencia (Valencia); the Instituto de Biología y Genética 
Molecular, Valladolid (Valladolid); the Hospital Provincial de Castellón, Castellón (Castellón); the Hospital de Cruces, Barakaldo-Bizkaia (Barakaldo); the Hospital 
Universitario Miguel Servet, Zaragoza (Zaragoza); the Hospital General Universitario de Elche, Elche (Elche); and the Centro de Investigación del Cáncer, Salamanca 
(Salamanca). 
b Sole mutation carriers in their respective families (not included in the penetrance study; [5]) 
c 
All identified female mutation carriers were considered eligible, but only those with complete data were included in the analyses
 
d 
Carriers from Vall d´Hebron were not included in the penetrance study [5]. These included 4 of 5 eligible obligate BRCA1 mutation carriers and 1 eligible obligate BRCA2 mutation 
carrier.
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Table 2: Distribution of mutation carriers according to study centre (CENTRE), censoring age (AGE) and  
year of birth (YOB), by type of cancer, affection status and gene mutated 
 BRCA1 mutation carriers, n (%) BRCA2 mutation carriers, n (%) 
 
 
BREAST CANCER 
Affected     Unaffected 
OVARIAN CANCER 
Affected     Unaffected 
BREAST CANCER 
Affected     Unaffected 
OVARIAN CANCER 
Affected   Unaffected 
CENTRE
*
 
  CNIO 
  Sant Pau 
  HCSC 
  ICO 
  Vall d´Hebron 
  FPGMX 
  Valencia 
  Others
a
 
p-valor
b
 
 
61 (22) 44 (18) 
46 (17) 40 (17) 
35 (13) 43 (18) 
31 (11) 21 (9) 
29 (11) 31 (13) 
28 (10) 31 (13) 
 
46 (17) 29 (12) 
0.3 
 
15 (21) 90 (20) 
  9 (12) 77 (17) 
13 (18) 65 (15) 
  5 (7) 47 (11) 
  5 (7) 55 (12) 
13 (18) 46 (10) 
 
13 (18) 62 (14) 
0.3 
 
64 (22) 53 (25) 
43 (15) 40 (19) 
35 (12) 37 (17) 
32 (11) 32 (15) 
 
   
32 (11) 18 (8) 
83 (28) 34 (16) 
0.01 
 
11 (31)      106 (23) 
  6 (17) 77 (16) 
  5 (14) 67 (14) 
  5 (14) 59 (13) 
 
 
  3 (9) 47 (10) 
  5 (14)      112 (24) 
0.8 
AGE 
  <25 
  25-29 
  30-34 
  35-39 
  40-44 
  45-49 
  50-54 
  55-59 
  60-64 
  65-69 
  70-79 
p-valor
c
 
 
  6 (2) 23 (10) 
23 (8) 24 (10) 
54 (20) 34 (14) 
57 (21) 34 (14) 
61 (22) 35 (15) 
36 (13) 28 (12) 
23 (8) 21 (9) 
  8 (3) 17 (7) 
  3 (1)   7 (3) 
  2 (1)   9 (4) 
  3 (1)   7 (3) 
0.2 
 
  0 (0) 29 (7) 
  0 (0) 47 (11) 
  6 (8) 82 (19) 
  6 (8) 85 (19) 
12 (16) 84 (19) 
17 (23) 47 (11) 
14 (19) 30 (7) 
10 (14) 15 (3) 
  2 (3)   8 (2) 
  4 (5)   7 (2) 
  2 (3)   8 (2) 
<0.001 
 
  2 (1) 21 (10) 
17 (6) 27 (13) 
44 (15) 36 (17) 
62 (21) 23 (11) 
58 (20) 25 (12) 
44 (15) 23 (11) 
26 (9) 19 (9) 
15 (5) 11 (5) 
10 (3) 12 (6) 
  5 (2) 11 (5) 
  6 (2)   6 (3) 
0.2 
 
  0 (0) 23 (5) 
  0 (0) 44 (10) 
  1 (3) 79 (17) 
  0 (0) 85 (18) 
  3 (9) 80 (17) 
  5 (14) 62 (13) 
  5 (14) 40 (9) 
  3 (9) 23 (5) 
10 (29) 12 (3) 
  5 (14) 11 (2) 
  3 (9)   9 (2) 
<0.001 
YOB 
  <1930 
  1930-39 
  1940-49 
  1950-59 
  1960-69 
  ≥1970 
p-valor
c
 
 
12 (4) 13 (5) 
20 (7) 14 (6) 
54 (20) 32 (13) 
87 (32) 45 (19) 
68 (25) 53 (22) 
35 (13) 82 (34) 
<0.001 
 
  5 (7) 20 (5) 
13 (18) 21 (5) 
18 (25) 68 (15) 
24 (33)      108 (24) 
  9 (12)      112 (25) 
  4 (5)        113 (26) 
<0.001 
 
16 (6)   9 (4) 
32 (11) 20 (9) 
54 (19) 20 (9) 
93 (32) 39 (18) 
71 (25) 40 (19) 
23 (8) 86 (40) 
<0.001 
 
  6 (17) 19 (4) 
13 (37) 39 (8) 
  9 (26) 65 (14) 
  4 (11)      128 (27) 
  3 (9)        108 (23) 
  0 (0)        109 (23) 
<0.001 
a 
Includes Valencia for carriers of mutations in BRCA1, and includes Vall d´Hebron and FPGMX for carriers of mutations in BRCA2 
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b 
p-value calculated using Pearson´s Chi-squared test  
c 
p-value calculated using logistic regression on the continuous variable
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Table 3: Estimated hazard ratios (HR) for breast and ovarian cancer associated with parity variables, for BRCA1 and BRCA2  
mutation carriers 
 Breast Cancer Ovarian Cancer 
BRCA1 mutation carriers 
HR
a
 (95%CI);  p-value 
BRCA2 mutation carriers 
HR
a
 (95%CI);  p-value 
BRCA1 mutation carriers 
HR
a
 (95%CI);  p-value 
BRCA2 mutation carriers 
HR
a
 (95%CI);  p-value 
Parity 
    Nulliparous 
    Parous 
 
Number of live-births 
 0  
 1 
 2 
 3 
 ≥4 
Trend (per live-birth) 
 
Age at first live birth 
    15-19 
    20-24 
    25-29 
    ≥30 
Trend (per 5 years)  
 
   1.00 
   0.82 (0.55-1.20); 0.3 
 
 
   1.00 
   0.93 (0.60-1.46); 0.8 
   0.83 (0.54-1.27); 0.4 
   0.64 (0.36-1.17); 0.1 
   0.64 (0.32-1.25); 0.2 
   0.88 (0.76-1.02); 0.08 
 
 
   0.81 (0.41-1.60); 0.5 
   1.00  
   0.76 (0.48-1.19); 0.2 
   0.65 (0.38-1.11); 0.1 
   0.90 (0.73-1.11); 0.3 
 
   1.00 
   0.66 (0.39-1.12); 0.1 
 
 
   1.00 
   0.69 (0.36-1.34): 0.3 
   0.68 (0.38-1.22); 0.2 
   0.54 (0.26-1.10); 0.09 
   0.72 (0.29-1.77); 0.5 
   0.88 (0.71-1.08); 0.2 
 
 
   0.83 (0.30-2.30); 0.7 
   1.00  
   1.15 (0.68-1.95); 0.6 
   1.16 (0.57-2.38); 0.7 
   1.13 (0.83-1.54); 0.4 
 
   1.00 
   0.41 (0.18-0.94); 0.03 
 
 
   1.00 
   0.33 (0.12-0.95): 0.04 
   0.40 (0.17-0.94); 0.04 
   0.74 (0.28-1.99); 0.6 
   0.15 (0.04-0.56); 0.005 
   0.80 (0.61-1.05); 0.1 
 
 
   0.85 (0.30-2.43); 0.8 
   1.00  
   1.07 (0.51-2.27); 0.9 
   0.40 (0.16-1.02); 0.06 
   0.65 (0.49-0.85); 0.001 
 
   1.00 
   0.62 (0.10-3.97); 0.6 
 
 
   1.00 
   0.87 (0.11-6.79); 0.9 
   0.36 (0.05-2.92); 0.3 
   0.61 (0.08-4.96); 0.6 
   1.87 (0.19-18.4); 0.6 
   1.21 (0.59-2.46); 0.6 
 
 
   0.78 (0.11-5.46); 0.8 
   1.00 
   0.70 (0.18-2.72); 0.6 
   0.26 (0.05-1.35); 0.1 
   0.63 (0.35-1.13); 0.1 
CI, confidence interval. 
 a adjusting for year of birth and study centre. 
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Table 4: Summary of published studies of parity as a modifier of breast cancer risk in BRCA1 and BRCA2 mutation carriers 
Authors (Year) Methodology Number
a
 Exposure(s) assessed RR (95% CI)
b
 
Jernstrom et al. (1999) 
[16] 
Conditional logistic regression 
analysis of matched case-control data 
from pooled female BRCA1 and 
BRCA2 mutation carriers aged ≤40. 
189/189 (BRCA1) 
47/47 (BRCA2) 
Pooled mutation carriers 
  Parity (ever vs. never) 
  Parity (per birth) 
 
1.71 (1.13-2.62) 
1.24 (1.04-1.47) 
Rebbeck et al. (2001) 
[20] 
Unconditional logistic regression 
analysis of affected and unaffected 
female BRCA1 and BRCA2 mutation 
carriers of all ages pooled. 
370/78 (BRCA1 and 
BRCA2 pooled) 
Pooled mutation carriers 
  Age at first birth  
      (<30 vs. ≥30 or nulliparous) 
 
 
0.33 (0.16-0.66) 
 
Cullinane et al. (2005) 
[14] 
(Expanded dataset, that 
includes that of Jernstrom 
et al. (1999) [16] 
Conditional logistic regression 
analysis of matched case-control data 
from female BRCA1 and BRCA2 
mutation carriers of all ages, by gene 
and by age (divided at age 50). 
934/934 (BRCA1) 
326/326 (BRCA2) 
BRCA1 mutation carriers 
  Parity (ever vs. never) 
  Parity (≥4 births vs. never) 
  Parity (per birth) 
BRCA2 mutation carriers 
  Parity (ever vs. never) 
  Parity (≥2 births vs. never) 
  Parity (per birth) 
      (per birth, age <50) 
      (per birth, age ≥50) 
 
0.94 (0.75-1.19) 
0.62 (0.41-0.94) 
0.94 (0.86-1.02) 
 
1.37 (0.93-2.03) 
1.53 (1.01-2.32) 
1.15 (1.00-1.33) 
1.17 (1.01-1.36) 
0.97 (0.58-1.53) 
Gronwald et al. (2006) 
[15] 
(data may be included in 
Cullinane et al., 2005) 
[14] 
Conditional logistic regression 
analysis of matched case-control data 
from female BRCA1 mutation 
carriers of all ages with mutations in 
BRCA1. 
348/348 (BRCA1) BRCA1 mutation carriers 
  Parity (per birth) 
   
 
1.2 (P
c
=0.02) 
 
Andrieu et al. (2006) [17] 
 
Weighted Cox regression analysis of 
affected and unaffected female 
BRCA1 and BRCA2 mutation carriers 
of all ages, by gene and by age 
(divided at age 40). 
602/585 (BRCA1) 
251/163 (BRCA2) 
BRCA1 mutation carriers 
  Parity (ever vs. never) 
  Age at 1
st
 birth (<20 vs. ≥30) 
BRCA2 mutation carriers 
  Parity (ever vs. never) 
  Age at 1
st
 birth (<20 vs. ≥20) 
Pooled mutation carriers 
  Parity (parous women only) 
      (per birth, all ages) 
      (per birth, age ≤40) 
      (per birth,  age >40) 
 
0.86 (0.64-1.15) 
1.72 (1.06-2.78) 
 
0.79 (0.46-1.37) 
0.5 (not given) 
 
 
0.86 (0.78-0.94) 
1.10 (0.90-1.34) 
0.85 (0.77-0.95) 
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Antoniou et al. (2006) 
[23] 
 
Weighted Cox regression analysis of 
affected and unaffected female 
BRCA1 and BRCA2 mutation carriers 
of all ages, by gene and by age 
(divided at age 40). 
248/218 (BRCA1) 
209/114 (BRCA2) 
BRCA1 mutation carriers 
  Parity (ever vs. never) 
      (ever vs. never, age ≤40) 
      (ever vs. never, age >40) 
  Age at 1
st
 birth (<20 vs. ≥30) 
BRCA2 mutation carriers 
  Parity (ever vs. never) 
      (ever vs. never, age ≤40) 
      (ever vs. never, age >40) 
  Age at 1
st
 birth (<20 vs. ≥30) 
Pooled mutation carriers 
  Parity (including nulliparous) 
      (per birth, all ages) 
 
0.53 (0.34-0.83) 
1.17 (0.55-2.52) 
0.34 (0.16-0.70) 
1.20 (0.61-2.38) 
 
0.58 (0.27-1.24) 
0.72 (0.42-1.24) 
1.21 (0.37-3.92) 
0.21 (0.09-0.48) 
 
 
0.90 (0.80-1.00) 
Kostopoulos et al. (2007) 
[19] 
Conditional logistic regression 
analysis of matched case-control data 
from female BRCA1 mutation 
carriers of all ages with mutations in 
BRCA1. 
1405/1405 (BRCA1) 
411/411 (BRCA2) 
Pooled mutation carriers 
  Age at 1
st
 birth (trend/year) 
 
1.01 (0.98-1.03) 
Present study Weighted Cox regression analysis of 
affected and unaffected female 
BRCA1 and BRCA2 mutation carriers 
of all ages, by gene 
276/239 (BRCA1) 
289/214 (BRCA2) 
BRCA1 mutation carriers 
  Parity (ever vs. never) 
  Parity (per birth) 
      (per birth, age ≤40) 
      (per birth, age >40) 
  Age at 1
st
 birth (trend/year) 
BRCA2 mutation carriers 
  Parity (ever vs. never) 
  Parity (per birth) 
      (per birth, age ≤40) 
      (per birth, age >40) 
  Age at 1
st
 birth (trend/year) 
Pooled mutation carriers 
  Parity (parous women only) 
      (per birth, all ages) 
      (per birth, age ≤40) 
      (per birth,  age >40) 
 
0.82 (0.55-1.20) 
0.88 (0.76-1.02) 
1.02 (0.81-1.29) 
0.82 (0.69-0.98) 
0.98 (0.94-1.02) 
 
0.66 (0.39-1.12) 
0.88 (0.71-1.08) 
0.97 (0.74-1.28) 
0.81 (0.63-1.04) 
1.03 (0.96-1.09) 
 
 
0.87 (0.77-0.98) 
0.99 (0.83-1.18) 
0.81 (0.70-0.94) 
a 
Number of affected carriers/number of unaffected carriers (gene in which a mutation is carried in parenthesis) 
b 
RR, estimate of relative risk associated with the exposure; CI, confidence interval  
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c 
P, p-value (95%CI not provided) 
 
 
